Information Provided By: 
Fly News Breaks for March 1, 2018
GBT
Mar 1, 2018 | 07:37 EDT
SunTrust analyst Yatin Suneja raised his price target on Global Blood Therapeutics to $80 after the company's Q4 earnings as well as the recent positive interim HOPE data that increased his conviction of a successful readout for GBT440's Phase 3 program. Suneja keeps his Buy rating, noting that while an accelerated approval based on the early efficacy data is possible, the management targets approval for Part B data in the first half of FY19.
News For GBT From the Last 2 Days
There are no results for your query GBT
